Last updated
Gilead Sciences: M&A Activity
Gilead Sciences acquired Tubulis, a Germany-based clinical-stage biotechnology company for up to USD 5.0 billion
Source: PR Newswire - Technology
- Who
- Gilead Sciences · Biotech & Pharma · Germany
- What happened
- Gilead Sciences acquired Tubulis, a Germany-based clinical-stage biotechnology company for up to USD 5.0 billion
- When
- 2026-04-07
- Source
- PR Newswire - Technology
- So what
- Gilead's acquisition of Tubulis commits it to integrating a clinical-stage ADC platform built around a proprietary linker-payload chemistry that was not on its books before.
The leadership read
Gilead's acquisition of Tubulis commits it to integrating a clinical-stage ADC platform built around a proprietary linker-payload chemistry that was not on its books before. The distinction matters: this is not a commercial asset acquisition where revenue machinery transfers with the deal. Tubulis is mid-pipeline, which means Gilead has purchased a technology thesis and a scientific organization simultaneously, and the operational clock now runs against clinical milestones, CMC scale-up, and the cross-jurisdictional regulatory filing work that bridges German biotech governance into a US-anchored submission architecture. This is one of twelve M&A signals we have tracked across the last 90 days, though the broader set is heterogeneous, financial services roll-ups, consumer retail, energy assets. The relevant comparable weight sits in biopharma specifically: cross-border acquisitions of clinical-stage platform companies at nine-figure-or-above valuations have continued at pace through Q1–Q2 2026, with acquirers consistently targeting differentiated modality platforms (ADCs, radiopharmaceuticals, targeted protein degraders) rather than late-stage single assets. Tubulis fits that pattern precisely. Across companies absorbing clinical-stage platform acquisitions at this scale, functional pressure concentrates in three areas: translational development leadership capable of running CMC and clinical operations across EU and US regulatory regimes simultaneously; portfolio integration leadership that can sequence pipeline assets without cannibalizing internal programs; and cross-border alliance management for the academic and CRO partnerships that platform-stage biotechs depend on and large acquirers routinely undervalue during integration.
Market context: Backdrop: a 95.4 (Cool) Talent Market Index (down 5.3 on the month) with EMEA activity rising (+5pts).
Gilead Sciences: 2 signals in the last 90 days — above the Biotech & Pharma median of 1 across 31 tracked companies; 0.1% of MitchelLake's Asia signal flow; 6 tracked across 216 days.
MitchelLake in this thematic
Also at Gilead Sciences →
More signals across Biotech & Pharma
M&A Activity · EMEA
Boehringer Ingelheim →Boehringer Ingelheim acquired Evax AG, a Swiss biotech company specializing in equine health, expanding its animal health portfolio.
M&A Activity · EMEA
Biogen →Biogen completed acquisition of Apellis Pharmaceuticals, a leader in complement-driven disease treatments
Leadership Change · EMEA
BioNTech →BioNTech's Chief Medical Officer Özlem Türeci is described as outgoing, per comments on the Q3 earnings call, as the company reviews its oncology pipeline (T-Pam, pumitamig, gotistobart).
Capital Raising · EMEA
Neobe Therapeutics →UK biotech Neobe Therapeutics raised $6.8M (£5M) in seed funding led by ARC Ventures, with participation from Faber, Macmillan Ventures, Proven Connect and Empirical Ventures, to advance its NEO22 engineered-bacteria cancer program toward an IND filing in 2028.
Leadership Change · EMEA
Harbour BioMed →Harbour BioMed (HKEX: 02142) appointed Vivian Feng as Head of External Collaboration, a new senior role overseeing partnerships with external parties.
Capital Raising · EMEA
mbiomics →mbiomics secured a further €12M, bringing its Series A to €30M to advance microbiome-based therapeutics (as reported in a roundup of European biotech financings).
Where this lands in our work
- Private Equity →
Ownership change resets the executive requirement — value-creation leadership follows the deal.
- Executive Search: EMEA →
Our EMEA practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record
